Catus Consult ApS: Financial statements 2024
CVR: 39791633
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Catus Consult ApS (CVR 39791633) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -9,400 and a net result of DKK -7,234 compared with DKK 0 the year before. Equity in the 2024 report amounted to DKK 43,294. The solvency ratio was 84.7%.
- Gross Profit
- DKK -9,400
- Profit/Loss
- DKK -7,234
- Equity
- DKK 43,294
- Total Assets
- DKK 51,094
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -9 t. | -7 t. | 43 t. | 0 |
| 2023 | - | - | 0 | 40 t. | - |
| 2022 | - | - | 0 | 40 t. | - |
| 2021 | - | 0 | 0 | 40 t. | - |
| 2020 | - | 30 t. | 23 t. | 19 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Catus Consult ApS has published its annual report for 2023. The net result was DKK 0.
About Catus Consult ApS
Catus Consult ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Isanans Pharma ApS and Isanans Pharma IVS. The management consists of Kamilla Rolsted. The company is owned by VAMI Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 680,675 and a net result of DKK 137,824 compared with DKK -7,234 the year before. Equity in the 2025 report amounted to DKK 181,118.